The Significance of Adaptive Design in R&D in Japan

Article Outline

• Abstract
• References
• Copyright

In the past decade, the number of drug and biological product submissions to the United States Food and Drug Administration has been slowly declining, while biomedical research spending has increased. A similar situation can also be seen in Japan: the number of domestic clinical trials is diminishing, and the cost of conducting a trial is rising. To prevent further decreases in the number of clinical trials, there is a need for an innovative strategy such as an adaptive design in research and development. Integrative celerity research aims to combine critical path and translational research, and seek update and participation in global clinical research. Participation in global studies through an adaptive design raises statistical concerns, which can be dealt with by adapting bridging studies. As a result of the restricted number of patients before approval in the adaptive design, safety issues must be guaranteed. Thus, establishing an effective and strong safety network between medical facilities is crucial. Japan's mission is to develop better drugs more efficiently and to investigate new drug methodologies for participation in global/Asian studies. Team work between clinical trial specialists, computer scientists, medical doctors, and statisticians is important for the success of both adaptive design and construction of a safety network between medical facilities in Japanese research and development.

Key Words:  adaptive design , critical path initiative , safety network

No full text is available. To read the body of this article, please view the PDF online.

Back to Article Outline

References 

1. US Food and Drug Administration  . FDA White Paper. Challenge and Opportunity on the Critical Path to New Medical Products . Rockville, MD: FDA; March 2004;
   • View In Article
2. Imura H . Strategic Initiative, Promotion of Integrative Celerity Research (ICR), Innovation in Health and Medicine . Tokyo, Japan: Center for Research and Development Strategy, Japan Science and Technology Agency; 2006; (CRDS-FY2006-SP-18-E).
   • View In Article
3. Center For Drug Evaluation, Department of Health, Executive Yuan, Taiwan, R.O.C. Bridging Studies. . Available from: www.cde.org.tw/bse_website/index.html
   • View In Article
4. The 1^st, 2^nd, 3^rd Kitasato–Harvard Symposium, Japan. Available from: www.pharm.kitasato-u.ac.jp/biostatis/
   • View In Article
5. Ministry of Health, Labor and Welfare, Japan. Comparison and Summary of Difference of J-GCP and ICH-GCP. [In Japanese] Available from: www.mhlw.go.jp/shingi/2007/02/dl/s0228-8u.pdf
   • View In Article
6. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical Practice E6(R1). Available from: www.ich.org/LOB/media/MEDIA482.pdf
   • View In Article